Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01914406
Other study ID # H-3-2010 030
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2011
Est. completion date October 2013

Study information

Verified date October 2023
Source Bispebjerg Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study was to examine the effects of high intensity aerobic interval training (AIT) versus moderate continuous training (CON) in heart transplant recipients.


Description:

Clinically stable heart transplant recipients > 12 month or more after HTx, age > 18 years, willing and capable of giving written informed consent for study participation and anticipated to be able to participate in the study for 12 months were included from the Heart Centre, Rigshospitalet, Copenhagen University Hospital. Patients were excluded due to unstable condition or postoperative complications, recent severe rejection episodes (>H1R < 3 month), physical disabilities which prevent participation and re-transplantation or multi-organtransplantation.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date October 2013
Est. primary completion date October 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: -stable Heart transplant recipients > 12 month or more after HTx, age > 18 years,< 80. willing and capable of giving written informed consent for study participation. Exclusion Criteria: unstable condition postoperative complications, recent severe rejection episodes (>H1R < 3 month), re-transplantation or multi-organtransplantation.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
high intense interval training
Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
continuous moderate training
Continued exercise 45 min.

Locations

Country Name City State
Denmark Cardiac Rehabilitation, Bispebjerg University Hospital Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Bispebjerg Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary VO2peak baseline test before randomization
follow-up after 12 weeks of exercise
follow-up after 5 month washout.
follow-up after second 12 weeks period of exercise.
baseline test (inclusion), follow-up 1(3 month), follow-up 2 (8 month), follow-up 3 (11 month).
Secondary Endothelial function (endoPAT) After the release of the cuff the hyperemic response was recorded and the reactive hyperemia index (RHI) was calculated automatic independent of operator. (endoPAT) baseline test (inclusion), follow-up 1(3 month), follow-up 2 (8 month), follow-up 3 (11 month).
Secondary Quality of Life (QoL)SF-36 SF-36, information on Quality of Life baseline test (inclusion), follow-up 1(3 month), follow-up 2 (8 month), follow-up 3 (11 month).
Secondary HADS-a, HADS-d anxiety and depression Symptoms of anxiety and depression measured by the Hospital Anxiety and Depression Scale (HADS). baseline test (inclusion), follow-up 1(3 month), follow-up 2 (8 month), follow-up 3 (11 month).
Secondary Bloodsamples/biomarkers. Samples cooled on ice, centrifuged for 10 minutes and the plasma transferred to microtubes and stored at -80°C. Biomarkers analysed at department of biomedicine at University of Copenhagen. baseline test (inclusion), follow-up 1(3 month), follow-up 2 (8 month), follow-up 3 (11 month).
Secondary augmentation index (AI), endoPAT Augmentation index (AI)derived from pulse wave analyses and is a measure of arterial stiffness, (EndoPAT). baseline test (inclusion), follow-up 1(3 month), follow-up 2 (8 month), follow-up 3 (11 month).
See also
  Status Clinical Trial Phase
Completed NCT02077764 - The GRAFT Study: Evaluation of Graft Function, Rejection and Cardiac Allograft Vasculopathy in First Heart Transplant Recipients. N/A
Terminated NCT01278745 - Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation Phase 2
Recruiting NCT06190171 - Respiratory Strength Training in Heart Transplant Recipients N/A
Completed NCT01912248 - Acute Effect of Strength Training on Blood Pressure in Cardiac Patients N/A
Active, not recruiting NCT01759966 - Autonomic Cardiovascular Control After Heart Transplantation
Completed NCT01796379 - High Intensity Training in de Novo Heart Transplant Recipients in Scandinavia N/A
Completed NCT02213770 - Long Term Effect of High-intensity Training After Heart Transplantation N/A
Completed NCT03662789 - Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients Phase 2/Phase 3